Frequencies of CD40+ cells (21.91 ± 7.58% vs. 31.64 ± 4.11%, p = 0.02) and CD83+ cells (28.08 ± 10.54% vs. 41.0 ± 11.28%, p = 0.06) were significantly decreased in BD mice treated with Abatacept compared to those in nontreated BD mice (Figures 2(f) and 2(g)). This evidence concerns the gene CD40 and Behcet disease.